ADPT Adaptive Biotechnologies Corp

Nasdaq adaptivebiotech.com


$ 17.29 $ 0.19 (1.11 %)    

Thursday, 16-Oct-2025 15:13:09 EDT
QQQ $ 598.28 $ -6.92 (-1.14 %)
DIA $ 459.35 $ -4.02 (-0.87 %)
SPY $ 659.63 $ -7.28 (-1.09 %)
TLT $ 91.40 $ 0.90 (0.99 %)
GLD $ 394.87 $ 3.72 (0.95 %)
$ 17.11
$ 17.15
$ 17.22 x 15
$ 17.29 x 107
$ 17.02 - $ 17.62
$ 4.27 - $ 17.14
2,047,116
na
2.61B
$ 1.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 03-03-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-02-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 02-14-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 02-15-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 02-24-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-12-2020 03-31-2020 10-Q
23 02-26-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-13-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 piper-sandler-maintains-overweight-on-adaptive-biotechnologies-raises-price-target-to-20

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the pri...

 jp-morgan-maintains-overweight-on-adaptive-biotechnologies-raises-price-target-to-17

JP Morgan analyst Sebastian Sandler maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price ...

 guggenheim-initiates-coverage-on-adaptive-biotechnologies-with-buy-rating-announces-price-target-of-20

Guggenheim analyst Subbu Nambi initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy rating and announces ...

 jp-morgan-maintains-overweight-on-adaptive-biotechnologies-raises-price-target-to-14

JP Morgan analyst Rachel Vatnsdal maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price ta...

 td-cowen-maintains-buy-on-adaptive-biotechnologies-raises-price-target-to-15

TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $1...

 piper-sandler-maintains-overweight-on-adaptive-biotechnologies-raises-price-target-to-15

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the pri...

 adaptive-biotechnologies-q2-eps-017-beats-024-estimate-sales-58879m-beat-49400m-estimate

Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate...

 cathie-woods-ark-invest-loads-up-on-absci-offloads-crispr-therapeutics

Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation.

 adaptive-biotechnologies-integrates-adaptives-clonosseq-test-for-mrd-assessment-in-lymphoid-malignancies-into-oncoemr-flatirons-cloud-based-emr-platform

Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetic...

 craig-hallum-initiates-coverage-on-adaptive-biotechnologies-with-buy-rating-announces-price-target-of-15

Craig-Hallum analyst John Wilkin initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy rating and announce...

 cathie-woods-ark-invest-continues-to-offload-tesla-as-elon-musk-moves-on-from-trump-administration

Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sa...

 adaptive-biotechnologies-says-ngs-based-clonoseq-test-for-mrd-assessment-to-be-included-in-30-presentations-at-asco-and-eha-2025

Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetic...

 piper-sandler-maintains-overweight-on-adaptive-biotechnologies-raises-price-target-to-13

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION